Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Voyager Therapeutics Inc.
DescriptionAdeno-associated virus (AAV)-based gene therapy designed to knock down expression of Huntingtin (HTT) protein
Molecular Target Huntingtin (HTT)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPreclinical
Standard IndicationHuntington's disease (HD)
Indication DetailsHuntington's disease (HD)
Regulatory Designation
PartnerCHDI Foundation Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today